In the ever-evolving world of liver disease, the shift from Nonalcoholic Steatohepatitis (NASH) to Metabolic Associated Steatotic Hepatitis (MASH) marks a revolutionary leap in our understanding and approach to treatment. This transition isn't merely a rebranding; it signifies a profound recognition of the intricate dance between metabolic dysfunction and liver health. As obesity and metabolic disorders increasingly take center stage in public health, MASH emerges as a clarion call for a deeper dive into the metabolic roots of liver disease. Understanding the transition from NASH to MASH, alongside the evolving drug therapies, is vital for healthcare providers and pat...
